Construction and validation of a novel prognostic nomogram for patients with poorly differentiated gastric neuroendocrine neoplasms

Table 2 Univariate and multivariate analysis of survival time of gastric cancer patients

Clinicopathological characteristics	Univariate analysis			Multivariate analysis
	HR	95%CI	P value	HR	95%CI	P value
Age (year)	1.030	1.012-1.048	0.001	1.040	1.019-1.061	< 0.001
BMI (kg/m2)	0.959	0.916-1.004	0.071	-	-	-
Gender
Female vs male	0.938	0.612-1.437	0.767	-	-	-
Smoking history
Yes vs no	1.120	0.821-1.528	0.474	-	-	-
Drinking history
Yes vs no	1.006	0.738-1.373	0.968	-	-	-
Pathological grade
MANEC vs NEC	0.770	0.546-1.087	0.137	-	-	-
CgA
Positive vs negative	0.768	0.556-1.061	0.109	-	-	-
Syn
Positive vs negative	1.745	0.646-4.710	0.272	-	-	-
CD56
Positive vs negative	1.073	0.734-1.568	0.717	-	-	-
Vascular cancer
Yes vs no	1.461	1.062-2.010	0.020	0.897	0.634-1.268	0.538
perineural invasion
Yes vs no	1.398	0.964-2.029	0.078	-	-	-
Ki-67 index (%)
≥ 70 vs < 70	1.786	1.240-2.571	0.002	1.504	1.022-2.214	0.038
Tumor diameter (cm)
≥ 3 vs < 3	2.713	1.470-5.006	0.001	0.775	0.369-1.628	0.502
Tumor morphology	-	-	0.107	-	-	-
Ulcer vs uplift	1.466	0.933-2.303	0.097	-	-	-
Others vs uplift	0.645	0.193-2.157	0.477	-	-	-
Tumor location	-	-	0.042	-	-	0.082
Middle third vs upper third	1.097	0.715-1.684	0.671	1.388	0.880-2.189	0.159
Lower third vs upper third	0.769	0.519-1.139	0.190	0.756	0.501-1.142	0.184
Others vs upper third	2.655	1.157-6.093	0.021	1.784	0.761-4.183	0.183
Invasion depth	-	-	< 0.001	-	-	0.040
T2 vs T1	3.003	0.846-10.874	0.089	2.224	0.582-8.490	0.242
T3 vs T1	4.824	1.493-15.590	0.009	2.288	0.594-8.819	0.229
T4 vs T1	11.766	3.728-37.133	< 0.001	3.764	0.972-14.575	0.055
Lymph node metastasis	-	-	< 0.001	-	-	< 0.001
N1 vs N0	1.534	0.853-2.759	0.153	1.229	0.654-2.308	0.522
N2 vs N0	3.335	1.966-6.658	< 0.001	2.746	1.518-4.968	0.001
N3 vs N0	8.491	5.117	< 0.001	4.534	2.416-8.355	< 0.001
Distant metastasis
M1 vs M0	4.808	3.396-6.808	< 0.001	2.513	1.666-3.792	< 0.001
TNM stage	-	-	< 0.001	-	-	-
II stage vs I stage	2.012	0.899-4.500	0.089	-	-
III stage vs I stage	5.502	2.649-11.428	< 0.001	-	-	-
IV stage vs I stage	16.746	7.837-35.784	< 0.001	-	-	-
PLR
High-group vs low-PLR	1.840	1.350-2.509	< 0.001	1.424	1.020-1.988	0.038
FBG
High-FBG vs low-FBG	2.386	1.746-3.260	< 0.001	1.153	0.821-1.620	0.410

HR: Hazard ratios; CI: Confidence interval; BMI: Body mass index; NEC: Neuroendocrine carcinoma; MANEC: Mixed adeno-neuroendocrine carcinoma; CgA: Chromogranin A; Syn: Synuclein; TNM: Tumor-node-metastasis; PLR: Platelet-to-lymphocyte ratio; FBG: Fibrinogen.